Could androgens be relevant to partly explain why men have lower life expectancy than women?

Journal of Epidemiology and Community Health

Volumn 70, Issue 4, 2016, Pages 324-328

  Schooling, C Mary ^a,b  

^a CITY UNIVERSITY OF NEW YORK   (United States)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN;

FEMALE; HEALTH DISPARITY; HUMAN; LIFE EXPECTANCY; MALE; PHYSIOLOGY; SEX DIFFERENCE;

ANDROGENS; FEMALE; HEALTH STATUS DISPARITIES; HUMANS; LIFE EXPECTANCY; MALE; SEX FACTORS;

EID: 84961262963     PISSN: 0143005X     EISSN: 14702738     Source Type: Journal    
DOI: 10.1136/jech-2015-206336     Document Type: Note

References (96)

1. Mathers CD, Boerma T, Ma FD. Global and regional causes of death. Br Med Bull 2009;92:7-32.
2. Ezzati M, Obermeyer Z, Tzoulaki I, et al. Contributions of risk factors and medical care to cardiovascular mortality trends. Nat Rev Cardiol 2015;12:508-30.
3. Lemaitre JF, Berger V, Bonenfant C, et al. Early-late life trade-offs and the evolution of ageing in the wild. Proc Biol Sci 2015;282:20150209.
4. Balaresque P, Poulet N, Cussat-Blanc S, et al. Y-chromosome descent clusters and male differential reproductive success: young lineage expansions dominate Asian pastoral nomadic populations. Eur J Hum Genet 2015;23:1413-22.
5. Mukhopadhyay A, Tissenbaum HA. Reproduction and longevity: secrets revealed by C. elegans. Trends Cell Biol 2007;17:65-71.
6. Solon-Biet SM, Walters KA, Simanainen UK, et al. Macronutrient balance, reproductive function, and lifespan in aging mice. Proc Natl Acad Sci U S A 2015;112:3481-6.
7. Manson JE, Chlebowski RT, Stefanick ML, et al. Menopausal hormone therapy and health outcomes during the intervention and extended post-stopping phases of the Women's Health Initiative randomized trials. JAMA 2013;310:1353-68.
8. Schooling CM, Xu L, Zhao J, et al. Norms hide causes-the example of testosterone. Int J Epidemiol 2014;43:1987-8.
9. Zhao J, Schooling CM. Promotion of "Low T" and citation bias in testosterone studies. Int J Cardiol 2015;184:510-11.
10. Shi Z, Araujo AB, Martin S, et al. Longitudinal changes in testosterone over five years in community-dwelling men. J Clin Endocrinol Metab 2013;98:3289-97.
11. Araujo AB, Dixon JM, Suarez EA, et al. Clinical review: endogenous testosterone and mortality in men: a systematic review and meta-analysis. J Clin Endocrinol Metab 2011;96:3007-19.
12. Ruige JB, Mahmoud AM, De BD, et al. Endogenous testosterone and cardiovascular disease in healthy men: a meta-analysis. Heart 2011;97:870-5.
13. Holmegard HN, Nordestgaard BG, Jensen GB, et al. Sex hormones and ischemic stroke: a prospective cohort study and meta-analyses. J Clin Endocrinol Metab 2015:jc20152687.
14. Schooling CM. Androgen activity, ischaemic heart disease and risk factors among men in NHANES III. Eur J Clin Invest 2013;43:1273-81.
15. Roddam AW, Allen NE, Appleby P, et al. Endogenous sex hormones and prostate cancer: a collaborative analysis of 18 prospective studies. J Natl Cancer Inst 2008;100:170-83.
16. Sissung TM, Price DK, Del RM, et al. Genetic variation: effect on prostate cancer. Biochim Biophys Acta 2014;1846:446-56.
17. Vigen R, O'Donnell CI, Baron AE, et al. Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels. JAMA 2013;310:1829-36.
18. Sharma R, Oni OA, Gupta K, et al. Normalization of testosterone level is associated with reduced incidence of myocardial infarction and mortality in men. Eur Heart J 2015;36:2706-15.
19. Baillargeon J, Urban RJ, Kuo YF, et al. Risk of myocardial infarction in older men receiving testosterone therapy. Ann Pharmacother 2014;48:1138-44.
20. Baillargeon J, Urban RJ, Morgentaler A, et al. Risk of venous thromboembolism in men receiving testosterone therapy. Mayo Clin Proc 2015;90:1038-45.
21. Faillie JL, Suissa S. [Immortal time bias in pharmacoepidemiological studies: definition, solutions and examples]. Therapie 2015;70: 259-63.
22. Xu L, Schooling CM. Differential risks in men and women for first and recurrent venous thrombosis: the role of genes and environment: comment. J Thromb Haemost 2015;13:884-6.
23. Bosco C, Bosnyak Z, Malmberg A, et al. Quantifying observational evidence for risk of fatal and nonfatal cardiovascular disease following androgen deprivation therapy for prostate cancer: a meta-analysis. Eur Urol 2015;68:386-96.
24. Nguyen PL, Je Y, Schutz FA, et al. Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials. JAMA 2011;306:2359-66.
25. Finkle WD, Greenland S, Ridgeway GK, et al. Increased risk of non-fatal myocardial infarction following testosterone therapy prescription in men. PLoS ONE 2014;9:e85805.
26. Liverman CT & Blazer DG (eds), Testosterone and Aging: Clinical Research Directions.Institute of Medicine (US) Committee on Assessing the Need for Clinical Trials of Testosterone Replacement Therapy. Washington: National Academies Press, 2004.
27. Chen Z, Tao S, Gao Y, et al. Genome-wide association study of sex hormones, gonadotropins and sex hormone-binding protein in Chinese men. J Med Genet 2013;50:794-801.
28. Vandenput L, Ohlsson C. Genome-wide association studies on serum sex steroid levels. Mol Cell Endocrinol 2014;382:758-66.
29. Trigunaite A, Dimo J, Jorgensen TN. Suppressive effects of androgens on the immune system. Cell Immunol 2015;294:87-94.
30. Kissick HT, Sanda MG, Dunn LK, et al. Androgens alter T-cell immunity by inhibiting T-helper 1 differentiation. Proc Natl Acad Sci U S A 2014;111:9887-92.
31. Sakiani S, Olsen NJ, Kovacs WJ. Gonadal steroids and humoral immunity. Nat Rev Endocrinol 2013;9:56-62.
32. Olsen NJ, Kovacs WJ. Evidence that androgens modulate human thymic T cell output. J Investig Med 2011;59:32-5.
33. Giefing-Kroll C, Berger P, Lepperdinger G, et al. How sex and age affect immune responses, susceptibility to infections, and response to vaccination. Aging Cell 2015;14:309-21.
34. Hofer MD, Cheng EY, Bury MI, et al. Androgen supplementation in rats increases the inflammatory response and prolongs urethral healing. Urology 2015;85:691-7.
35. Lai JJ, Lai KP, Chuang KH, et al. Monocyte/macrophage androgen receptor suppresses cutaneous wound healing in mice by enhancing local TNF-alpha expression. J Clin Invest 2009;119:3739-51.
36. Bernin H, Lotter H. Sex bias in the outcome of human tropical infectious diseases: influence of steroid hormones. J Infect Dis 2014;209(Suppl 3): S107-13.
37. Guerra-Silveira F, Abad-Franch F. Sex bias in infectious disease epidemiology: patterns and processes. PLoS ONE 2013;8:e62390.
38. Cutolo M, Balleari E, Giusti M, et al. Androgen replacement therapy in male patients with rheumatoid arthritis. Arthritis Rheum 1991;34: 1-5.
39. Booji A, Biewenga-Booji CM, Huber-Bruning O, et al. Androgens as adjuvant treatment in postmenopausal female patients with rheumatoid arthritis. Ann Rheum Dis 1996;55:811-15.
40. Chang C, Lee SO, Yeh S, et al. Androgen receptor (AR) differential roles in hormone-related tumors including prostate, bladder, kidney, lung, breast and liver. Oncogene 2014;33:3225-34.
41. Zhang Y. Understanding the gender disparity in bladder cancer risk: the impact of sex hormones and liver on bladder susceptibility to carcinogens. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev 2013;31:287-304.
42. He D, Li L, Zhu G, et al. ASC-J9 suppresses renal cell carcinoma progression by targeting an androgen receptor-dependent HIF2alpha/VEGF signaling pathway. Cancer Res 2014;74:4420-30.
43. Kalra M, Mayes J, Assefa S, et al. Role of sex steroid receptors in pathobiology of hepatocellular carcinoma. World J Gastroenterol 2008;14: 5945-61.
44. Harlos C, Musto G, Lambert P, et al. Androgen pathway manipulation and survival in patients with lung cancer. Horm Cancer 2015;6:120-7.
45. Sukocheva OA, Li B, Due SL, et al. Androgens and esophageal cancer: What do we know? World J Gastroenterol 2015;21:6146-56.
46. Amos-Landgraf JM, Heijmans J, Wielenga MC, et al. Sex disparity in colonic adenomagenesis involves promotion by male hormones, not protection by female hormones. Proc Natl Acad Sci U S A 2014;111:16514-19.
47. Swirski FK, Nahrendorf M. Leukocyte behavior in atherosclerosis, myocardial infarction, and heart failure. Science 2013;339:161-6.
48. Tabas I, Glass CK. Anti-inflammatory therapy in chronic disease: challenges and opportunities. Science 2013;339:166-72.
49. Nikiforov SV, Mamaev VB. The development of sex differences in cardiovascular disease mortality: a historical perspective. Am J Public Health 1998;88:1348-53.
50. Bhasin S, Pencina M, Jasuja GK, et al. Reference ranges for testosterone in men generated using liquid chromatography tandem mass spectrometry in a community-based sample of healthy nonobese young men in the Framingham Heart Study and applied to three geographically distinct cohorts. J Clin Endocrinol Metab 2011;96:2430-9.
51. Barker-Collo S, Bennett DA, Krishnamurthi RV, et al. Sex differences in stroke incidence, prevalence, mortality and disability-adjusted life years: results from the Global Burden of Disease Study 2013. Neuroepidemiology 2015;45:203-14.
52. Ajayi AA, Mathur R, Halushka PV. Testosterone increases human platelet thromboxane A2 receptor density and aggregation responses. Circulation 1995;91:2742-7.
53. Ajayi AA, Halushka PV. Castration reduces platelet thromboxane A2 receptor density and aggregability. QJM 2005;98:349-56.
54. Stone NJ, Robinson J, Lichtenstein AH, et al., American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2013 ACC/AHA Guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014;63(25 Pt B):2889-934.
55. Tunstall-Pedoe H. Myth and paradox of coronary risk and the menopause. Lancet 1998;351:1425-7.
56. [No authors listed]. The Coronary Drug Project. Findings leading to discontinuation of the 2.5-mg day estrogen group. The coronary Drug Project Research Group. JAMA 1973;226:652-7.
57. FDA adding general warning to testosterone products about potential for venous blood clots. 2014. http://www.fda.gov/Drugs/DrugSafety/ucm401746.htm
58. Health Canada. Information Update-Possible cardiovascular problems associated with testosterone products. 2014. http://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2014/40587a-eng.php
59. European Medicines Agency. No consistent evidence of an increased risk of heart problems with testosterone medicines. 2014. http://www.ema. europa.eu/ema/index jsp?curl=pages/news_and_ events/news/2014/11/news_detail_002218. jsp&mid=WC0b01ac058004d5c1
60. FDA. FDA Drug Safety Communication: FDA cautions about using testosterone products for low testosterone due to aging; requires labeling change to inform of possible increased risk of heart attack and stroke with use. 2015. http://www.fda.gov/Drugs/DrugSafety/ucm436259.htm
61. Safety Concerns Slow Sales of Testosterone Therapy.2014 http://www.bloomberg.com/bw/articles/2014-11-06/safety-concerns-hurt-sales-oftestosterone-replacement-therapy
62. What's Next For The Thousands Of Angry Men Suing Over Testosterone? 2015. http://www.forbes.com/sites/arleneweintraub/2015/04/06/whats-next-for-thethousands-of-angry-men-suing-over-testosterone/
63. Fernandez-Balsells MM, Murad MH, Lane M, et al. Clinical review 1: adverse effects of testosterone therapy in adult men: a systematic review and meta-analysis. J Clin Endocrinol Metab 2010;95:2560-75.
64. Schooling CM, Zhao J. Higher adiponectin and lower hemoglobin levels in older men: causal or confounded by androgens? J Intern Med 2015;278: 95-6.
65. Morrison JA, Barton BA, Biro FM, et al. Sex hormones and the changes in adolescent male lipids: longitudinal studies in a biracial cohort. J Pediatr 2003;142:637-42.
66. Zhao J, Jiang C, Lam TH, et al. Genetically predicted testosterone and cardiovascular risk factors in men: a Mendelian randomization analysis in the Guangzhou Biobank Cohort Study. Int J Epidemiol 2014;43:140-8.
67. Zhao J, Jiang C, Lam TH, et al. Genetically predicted testosterone and electrocardiographic QT interval duration in Chinese: a Mendelian randomization analysis in the Guangzhou Biobank Cohort Study. Int J Epidemiol 2015;44:613-20.
68. Calof OM, Singh AB, Lee ML, et al. Adverse events associated with testosterone replacement in middle-aged and older men: a meta-analysis of randomized, placebo-controlled trials. J Gerontol A Biol Sci Med Sci 2005;60:1451-7.
69. Haddad RM, Kennedy CC, Caples SM, et al. Testosterone and cardiovascular risk in men: a systematic review and meta-analysis of randomized placebo-controlled trials. Mayo Clin Proc 2007;82:29-39.
70. Xu L, Freeman G, Cowling BJ, et al. Testosterone and cardiovascular events among men: a systematic review and meta-analysis of placebo-controlled randomized trials. BMC Med 2013;11:108.
71. Corona G, Maseroli E, Rastrelli G, et al. Cardiovascular risk associated with testosteroneboosting medications: a systematic review and meta-analysis. Expert Opin Drug Saf 2014;13: 1327-51.
72. Basaria S, Harman SM, Travison TG, et al. Effects of testosterone administration for 3 years on subclinical atherosclerosis progression in older men with low or low-normal testosterone levels: a randomized clinical trial. JAMA 2015;314:570-81.
73. Eyben FE, Graugaard C, Vaeth M. All-cause mortality and mortality of myocardial infarction for 989 legally castrated men. Eur J Epidemiol 2005;20: 863-9.
74. Swerdlow AJ, Higgins CD, Schoemaker MJ, et al. Mortality in patients with Klinefelter syndrome in Britain: a cohort study. J Clin Endocrinol Metab 2005;90:6516-22.
75. [No authors listed]. Klinefelter's syndrome and diabetes mellitus. Lancet 1966;2:747-8.
76. Gale EA, Gillespie KM. Diabetes and gender. Diabetologia 2001;44:3-15.
77. Grossmann M, Hoermann R, Wittert G, et al. Effects of testosterone treatment on glucose metabolism and symptoms in men with type 2 diabetes and the metabolic syndrome: a systematic review and meta-analysis of randomized controlled clinical trials. Clin Endocrinol (Oxf ) 2015;83:344-51.
78. Tong G, Hua X, Zhong Y, et al. Intensive insulin therapy increases sex hormone-binding globulin in newly diagnosed type 2 diabetic patients. Eur J Endocrinol 2014;170:237-45.
79. Ahmad OS, Morris JA, Mujammami M, et al. A Mendelian randomization study of the effect of type-2 diabetes on coronary heart disease. Nat Commun 2015;6:7060.
80. Keene D, Price C, Shun-Shin MJ, et al. Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta-analysis of randomised controlled trials including 117,411 patients. BMJ 2014;349:g4379.
81. Ridker PM, Luscher TF. Anti-inflammatory therapies for cardiovascular disease. Eur Heart J 2014;35:1782-91.
82. Fordyce CB, Roe MT, Ahmad T, et al. Cardiovascular drug development: is it dead or just hibernating? J Am Coll Cardiol 2015;65:1567-82.
83. Schulte DM, Hahn M, Oberhauser F, et al. Caloric restriction increases serum testosterone concentrations in obese male subjects by two distinct mechanisms. Horm Metab Res 2014;46:283-6.
84. Schooling CM, Au Yeung SL, Freeman G, et al. The effect of statins on testosterone in men and women, a systematic review and meta-analysis of randomized controlled trials. BMC Med 2013;11:57.
85. Stoffer SS, Hynes KM, Jiang NS, et al. Digoxin and abnormal serum hormone levels. JAMA 1973;225: 1643-4.
86. Chevalier N, Fenichel P. Endocrine disruptors: new players in the pathophysiology of type 2 diabetes? Diabetes Metab 2015;41:107-15.
87. Cieri RL, Churchill SE, Franciscus RG, et al. Craniofacial feminization, social tolerance, and the origins of behavioral modernity. Curr Anthropol 2014;55:419-43.
88. Sewani-Rusike CR, Mudambo KS, Tendaupenyu G, et al. Effects of the Zimbabwe Defence Forces training programme on body composition and reproductive hormones in male army recruits. Cent Afr J Med 2000;46:27-31.
89. Liu W, Ramirez J, Gamazon ER, et al. Genetic factors affecting gene transcription and catalytic activity of UDP-glucuronosyltransferases in human liver. Hum Mol Genet 2014;23:5558-69.
90. Rowland A, Miners JO, Mackenzie PI. The UDP-glucuronosyltransferases: their role in drug metabolism and detoxification. Int J Biochem Cell Biol 2013;45:1121-32.
91. Strassburg CP, Strassburg A, Kneip S, et al. Developmental aspects of human hepatic drug glucuronidation in young children and adults. Gut 2002;50:259-65.
92. Sten T, Finel M, Ask B, et al. Non-steroidal anti-inflammatory drugs interact with testosterone glucuronidation. Steroids 2009;74:971-7.
93. Zhang JY, Zhan J, Cook CS, et al. Involvement of human UGT2B7 and 2B15 in rofecoxib metabolism. Drug Metab Dispos 2003;31:652-8.
94. Yamanaka H, Nakajima M, Katoh M, et al. Trans-3'-hydroxycotinine O-and N-glucuronidations in human liver microsomes. Drug Metab Dispos 2005;33:23-30.
95. Trelle S, Reichenbach S, Wandel S, et al. Cardiovascular safety of non-steroidal antiinflammatory drugs: network meta-analysis. BMJ 2011;342:c7086.
96. Mills EJ, Thorlund K, Eapen S, et al. Cardiovascular events associated with smoking cessation pharmacotherapies: a network meta-analysis. Circulation 2014;129:28-41.